Compare Palantir Technologies Inc (PLTR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Recursion Pharmaceuticals Inc — how do they compare? Palantir Technologies Inc trades at $199.95 (market cap $477.68B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B). The key difference: Palantir Technologies Inc is far larger — about 223.2× Recursion Pharmaceuticals Inc's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Palantir Technologies Inc for 78 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| PLTR | RXRX | |
|---|---|---|
Market Cap | $477.68B | $2.14B |
Volume | 41,744,992 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $207.18 | $6.79 |
52-Week Low | $107.27 | $2.84 |
Typical Hold Time | 78 Days | 22 Days |
Enterprise Value | $468.48B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $194.04, up 1.02% with a bullish technical outlook and strong fundamental momentum. The stock shows robust revenue growth of 56.2% in 2025, reaching $4.48 billion, with net income surging to $1.63 billion. Recent partnerships with Armada for sovereign AI infrastructure and consistent earnings beats highlight operational strength, though valuation metrics remain elevated with a P/E of 165.91.
The outlook remains positive with analyst consensus at Buy (53.84%) and a $191.69 price target. Key opportunities include AI platform expansion and commercial customer growth to 870, while risks involve high valuation sensitivity and competitive pressures. The stock trades near recent highs with support at $191 and resistance at $195.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
